Gilead Sciences: Why HIV Sales Could Save the Day
May 27, 2016 at 10:29 AM EDT
Yes, the focus with Gilead Sciences ( GILD ) always seems to be its hepatitis-C business . Leerink's Geoffrey Porges , however, argues that Gilead's HIV sales could double by 2020. He explains:
